The renoprotective potential of pentoxifylline in chronic kidney disease

Journal of the Chinese Medical Association

Volumn 68, Issue 3, 2005, Pages 99-105

  Lin, Shuei Liong ^a,b   Chiang, Wen Chih ^a,b   Chen, Yung Ming ^a,b   Lai, Chun Fu ^a,b   Tsai, Tun Jun ^a,b   Hsieh, Bor Shen ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Angiotensin II; Chronic kidney disease; Pentoxifylline

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR;

BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DYSPEPSIA; EXTRACELLULAR MATRIX; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HUMAN; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MONOTHERAPY; NAUSEA; NEPHROTIC SYNDROME; NONHUMAN; PROTEIN RESTRICTION; PROTEINURIA; RENAL PROTECTION; REVIEW; CHRONIC KIDNEY FAILURE; DRUG EFFECT;

CELL PROLIFERATION; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROTEINURIA;

EID: 16844381073     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70228-X     Document Type: Review

References (67)

1. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 1987;34:50-97.
2. Dousa TP. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 1999;55:29-62.
3. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001;108:671-80.
4. Meskini N, Nemoz G, Okyayuz-Baklouti I, Lagarde M, Prigent AF. Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem Pharmacol 1994;47:781-8.
5. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Leuchte H, Grimminger F, Seeger W, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;281:1361-8.
6. Blagosklonnaia IaV, Mamedov R, Kozlov VV, Emanuel VL, Kudriashova MI. Effect of trental on indices of kidney function in diabetes mellitus. Probl Endokrinol (Mosk) 1982;28:3-8. [In Russian]
7. Solerte SB, Fioravanti M, Bozzetti A, Schifino N, Patti AL, Fedele P, Viola C, et al. Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study. Acta Diabetol 1986;23:171-7.
8. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR, Garcia-Bulnes G, Salas-Ramirez M, Amato D. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 1995;43:116-21.
9. Tsai TJ, Lin RH, Chang CC, Chen YM, Chen CF, Ko FN, Teng CM. Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 1995; 70:91-100.
10. Albornoz LE, Sanchez SB, Bandi JC, Canteros G, de las Heras M, Mastai RC. Pentoxifylline reduces nephrotoxicity associated with cyclosporine in the rat by its theological properties. Transplantation 1997;64:1404-7.
11. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macia M, Mendez ML, et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 1999; 33:458-63.
12. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, Tsai TJ. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 1999;56:932-43.
13. Ducloux D, Bresson-Vautrin C, Chalopin JM. Use of pentoxifylline in membranous nephropathy. Lancet 2001;357: 1672-3.
14. Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF-α monoclonal antibody and by pentoxifylline. Lupus 2001;10:23-31.
15. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 2002;13:2916-29.
16. Lin SL, Chen RH, Chen YM, Chiang WC, Tsai TJ, Hsieh BS. Pentoxifylline inhibits platelet-derived growth factor-stimulated cyclin D1 expression in mesangial cells by blocking Akt membrane translocation. Mol Pharmacol 2003;64:811-22.
17. Navarro JF, Mora C, Muros M, Maca M, Garca J. Effects of pentoxifylline administration on urinary N-acetyl-β-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective randomized study. Am J Kidney Dis 2003; 42:264-70.
18. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour necrosis factor-α and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 2004;19:1106-15.
19. Paap CM, Simpson KS, Horton MW, Schaefer KL, Lassman HB, Sack MR. Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency. Ann Pharmacother 1996;30:724-9.
20. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307: 652-9.
21. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996;7:653-60.
22. Taal MW, Zandi-Nejad K, Weening B, Shahsafaei A, Kato S, Lee KW, Ziai F, et al. Pro-inflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 2000;58:1664-76.
23. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992;41:297-309.
24. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.
25. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000;11:25-38.
26. Strutz F, Zeisberg M, Hemmerlein B, Sattler B, Hummel K, Becker V, Muller GA. Basic fibroblast growth factor (FGF-2) expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int 2000; 57:1521-38.
27. Anders HJ, Vielhauer V, Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003;63:401-15.
28. Donadelli R, Zanchi C, Morigi M, Buelli S, Batani C, Tomasoni S, Corna D, et al. Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor κB- and p38 mitogen-activated protein kinase-dependent pathways. J Am Soc Nephrol 2003;14:2436-46.
29. Chen YM, Hu-Tsai MI, Lin SL, Tsai TJ, Hsieh BS. Expression of CX3CL1/fractalkine by mesangial cells in vitro and in acute anti-Thy1 glomerulonephritis in rats. Nephrol Dial Transplant 2003;18:2505-14.
30. Chen YM, Tu CJ, Hung KY, Wu KD, Tsai TJ, Hsieh BS. Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-κB down-regulation. Br J Pharmacol 2003; 138:950-8.
31. Dousa TP. Signaling role of PDE isozymes in pathobiology of glomerular mesangial cells. Studies in vitro and in vivo. Cell Biochem Biophys 1998;29:19-34.
32. Dumaz N, Marais R. Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem 2003;278:29819-23.
33. Chini CS, Chini EN, Williams JM, Matousovic K, Dousa TP. Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV. Kidney Int 1994;46:28-36.
34. Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, Dousa TP. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J Clin Invest 1996;98: 262-70.
35. Klahr S, Morrissey J. Progression of chronic renal disease. Am J Kidney Dis 2003;41:S3-7.
36. Heystek HC, Thierry AC, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 2003;15:827-35.
37. Shimizu E, Kobayashi Y, Oki Y, Kawasaki T, Yoshimi T, Nakamura H. OPC-13013, a cyclic nucleotide phosphodiesterase type III inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells. Life Sci 1999;64: 2081-8.
38. Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, Kim HJ, Takizawa H, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 2002;26:694-701.
39. Rao KM, Currie MS, McCachren SS, Cohen HJ. Pentoxifylline and other methyl xanthines inhibit interleukin-2 receptor expression in human lymphocytes. Cell Immunol 1991;135: 314-25.
40. Rieckmann P, Weber F, Gunther A, Martin S, Bitsch A, Broocks A, Kitze B, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996;64:193-200.
41. Strutz F, Heeg M, Kochsiek T, Siemers G, Zeisberg M, Muller GA. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant 2000;15:1535-46.
42. Lee KS, Cottam HB, Houglum K, Wasson DB, Carson D, Chojkier M. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity. Am J Physiol 1997;273:1094-100.
43. Chen YM, Wu KD, Tsai TJ, Hsieh BS. Pentoxifylline inhibits PDGF-induced proliferation of and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 1999;3:773-83.
44. Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide-induced tumour necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995;48:747-57.
45. Hecht M, Muller M, Lohmann-Matthes ML, Emmendorffer A. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J Leukoc Biol 1995;57:242-9.
46. Krakauer T. Induction of CC chemokines in human peripheral blood mononuclear cells by staphylococcal exotoxins and its prevention by pentoxifylline. J Leukoc Biol 1999;66:158-64.
47. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int 1998;53:1608-15.
48. Wang Y, Rangan GK, Tay YC, Wang Y, Harris DCH. Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor-κB in proximal tubule cells. J Am Soc Nephrol 1999;10:1204-13.
49. Cottam HB, Shih H, Tehrani LR, Wasson DB, Carson DA. Substituted xanthines, pteridinediones, and related compounds as potential anti-inflammatory agents. Synthesis and biological evaluation of inhibitors of tumour necrosis factor alpha. J Med Chem 1996;39:2-9.
50. Chen YM, Chiang WC, Lin SL, Wu KD, Tsai TJ, Hsieh BS. Dual regulation of TNF-α-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle sells by NF-κB and AP-1: modulation by type III phosphodiesterase inhibition. J Pharmacol Exp Ther 2004;309:978-86.
51. Galindo-Rodriguez G, Bustamante R, Esquivel-Nava G, Salazar-Exaire D, Vela-Ojeda J, Vadillo-Buenfil M, Avina-Zubieta JA. Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. J Rheumatol 2003;30:2382-4.
52. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med 1993;329:977-86.
53. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998;352: 837-53.
54. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-84.
55. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998;31:954-61.
56. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
57. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
58. Parving HH, Lehnert H, Brochner-Mortensen I, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
59. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
60. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
61. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A. Combining an anti-proteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999;10: 1542-9.
62. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH. Renoprotection: one or many therapies? Kidney Int 2001;59:1211-26.
63. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomized controlled trial of dual blockage of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microabluminuria (CALM) study. BMJ 2000;321:1440-4.
64. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002;13:2898-908.
65. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003;14:1816-24.
66. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal discase (COOPERATE): a randomized controlled trial. Lancet 2003; 361:117-24.
67. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8.